APA (7th ed.) Citation

Hameed, M., Habib, A., Khan, A. M., Laharwal, M. M., Mewawalla, P., McKenna, M., . . . Friend, R. (2026). A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment—USMIRC Group. Cancers, 18(5), 740. https://doi.org/10.3390/cancers18050740

Chicago Style (17th ed.) Citation

Hameed, Maha, et al. "A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment—USMIRC Group." Cancers 18, no. 5 (2026): 740. https://doi.org/10.3390/cancers18050740.

MLA (9th ed.) Citation

Hameed, Maha, et al. "A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment—USMIRC Group." Cancers, vol. 18, no. 5, 2026, p. 740, https://doi.org/10.3390/cancers18050740.